TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

CORLANOR

IVABRADINE HYDROCHLORIDE
Approved 2015-04-15
2
Indications
--
Phase 3 Trials
2
Priority Reviews
10
Years on Market

Details

Status
Discontinued
First Approved
2015-04-15
Routes
ORAL
Dosage Forms
TABLET, SOLUTION

Companies

Active Ingredient: IVABRADINE HYDROCHLORIDE

CORLANOR Approval History

Loading approval history...

What CORLANOR Treats

2 FDA approvals

Originally approved for its first indication in 2015 . Covers 2 distinct patient populations.

  • Other (2)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CORLANOR FDA Label Details

Pro

CORLANOR Patents & Exclusivity

Latest Patent: Jun 2027
Exclusivity: Oct 2026

Patents (36 active)

US7867996*PED Expires Jun 12, 2027
US7867996 Expires Dec 12, 2026
US7879842*PED Expires Aug 22, 2026
US7361649*PED Expires Aug 22, 2026
US7361650*PED Expires Aug 22, 2026
US7361649 Expires Feb 22, 2026
US7879842 Expires Feb 22, 2026
US7361650 Expires Feb 22, 2026
+ 26 more patents

Exclusivity

ODE-234 Until Apr 2026
PED Until Oct 2026
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.